Metagenomi Therapeutics Reports Results for Quarter Ended June 30, 2026

What Happened
Metagenomi Therapeutics, Inc. (MGX) announced its financial results for the quarter ended June 30, 2026 and provided additional business updates in a press release dated August 10, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8‑K filed August 10, 2026. The Form 8‑K was signed by Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer.

Key Details

• Announcement date: August 10, 2026 (Form 8‑K filing).
• Period covered: quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 to the Form 8‑K (read the exhibit for the full financial figures and business updates).
• Form items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters
This filing signals that Metagenomi has released its latest quarterly results and business updates; investors should review the Exhibit 99.1 press release for revenue, net income/loss, cash position, guidance, or other material metrics that affect valuation and near‑term plans. Because the Form 8‑K references the press release rather than embedding detailed financial tables in the body of the filing, retail investors should read the press release and the company’s recent SEC filings (10‑Q/10‑K) to get the full numeric results and context for any operational or program updates.